Last reviewed · How we verify
Lactobacillus plantarum strain 299v
Lactobacillus plantarum strain 299v is a probiotic bacterium that modulates the gut microbiome and enhances intestinal barrier function and immune tolerance.
Lactobacillus plantarum strain 299v is a probiotic bacterium that modulates the gut microbiome and enhances intestinal barrier function and immune tolerance. Used for Prevention or mitigation of chemotherapy-induced gastrointestinal toxicity in pediatric cancer patients, Support of immune recovery and reduction of infection risk in pediatric hematopoietic stem cell transplant recipients.
At a glance
| Generic name | Lactobacillus plantarum strain 299v |
|---|---|
| Also known as | DSM 9843, LACTIPLANTIBACILLUS PLANTARUM 299V, Lp 299v |
| Sponsor | Children's Oncology Group |
| Drug class | Live biotherapeutic product; probiotic |
| Modality | Biologic |
| Therapeutic area | Oncology; Immunology |
| Phase | Phase 3 |
Mechanism of action
This live biotherapeutic product colonizes the gastrointestinal tract and produces metabolites that strengthen tight junctions, reduce pathogenic bacterial translocation, and promote regulatory T cell differentiation. By restoring eubiotic balance and reducing systemic inflammation, it may mitigate treatment-related toxicities and support immune homeostasis in pediatric cancer patients undergoing chemotherapy or hematopoietic stem cell transplantation.
Approved indications
- Prevention or mitigation of chemotherapy-induced gastrointestinal toxicity in pediatric cancer patients
- Support of immune recovery and reduction of infection risk in pediatric hematopoietic stem cell transplant recipients
Common side effects
- Gastrointestinal disturbance (mild)
- Bacteremia or sepsis (rare, in severely immunocompromised patients)
Key clinical trials
- Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant (PHASE3)
- Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department (NA)
- Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain (NA)
- Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome (PHASE4)
- Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lactobacillus plantarum strain 299v CI brief — competitive landscape report
- Lactobacillus plantarum strain 299v updates RSS · CI watch RSS
- Children's Oncology Group portfolio CI